RxDoctor Payments Data

Elizabeth Devader

Nurse Practitioner · Topeka, KSNPI 1427748722

Payments from drug & device makers

$1,593in general payments, 2019–2025

Across 42 payments — averaging $37.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$486
  • Novo Nordisk$292
  • Insulet Corporation$284
  • Averitas Pharma Inc.$123
  • Corcept Therapeutics$110
  • Amgen$97
  • plus $200 from 5 others

What the payments were for

  • Food & beverage$1,56198%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,593 in reported general payments places this provider in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$64,553
Medicare patients
226
Services billed
3,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide236$271,066
JardianceEmpagliflozin173$159,115
MounjaroTirzepatide89$103,951
JanuviaSitagliptin Phosphate51$50,045
TrulicityDulaglutide43$47,439
Tresiba Flextouch U-100Insulin Degludec77$46,326
Synjardy XrEmpagliflozin/Metformin Hcl42$34,695
FarxigaDapagliflozin Propanediol29$23,403
Soliqua 100-33Insulin Glargine/Lixisenatide11$19,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$12,738
Novolog FlexpenInsulin Aspart48$9,846
SynjardyEmpagliflozin/Metformin Hcl13$7,666
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,006
Fiasp FlextouchInsulin Aspart (Niacinamide)11$6,875
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$6,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$292$271,066236 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$41$19,70411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →